As of 2025-12-22, the EV/EBITDA ratio of Rapid Dose Therapeutics Corp (DOSE.CN) is -7.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. DOSE.CN's latest enterprise value is 24.67 mil CAD. DOSE.CN's TTM EBITDA according to its financial statements is -3.31 mil CAD. Dividing these 2 quantities gives us the above DOSE.CN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.0x - 7.6x | 6.3x |
| Forward P/E multiples | 5.0x - 7.6x | 6.3x |
| Fair Price | (0.16) - (0.23) | (0.20) |
| Upside | -213.7% - -256.8% | -235.3% |
| Date | EV/EBITDA |
| 2025-12-18 | -7.05 |
| 2025-12-17 | -7.25 |
| 2025-12-16 | -7.45 |
| 2025-12-15 | -7.85 |
| 2025-12-12 | -8.06 |
| 2025-12-09 | -7.85 |
| 2025-12-08 | -7.85 |
| 2025-12-05 | -7.85 |
| 2025-12-04 | -8.06 |
| 2025-11-28 | -8.06 |
| 2025-11-26 | -8.46 |
| 2025-11-24 | -8.46 |
| 2025-11-21 | -9.26 |
| 2025-11-20 | -8.46 |
| 2025-11-19 | -8.86 |
| 2025-11-18 | -8.06 |
| 2025-11-17 | -8.06 |
| 2025-11-14 | -8.06 |
| 2025-11-12 | -7.65 |
| 2025-11-11 | -7.05 |
| 2025-11-10 | -7.65 |
| 2025-11-07 | -7.65 |
| 2025-11-05 | -7.65 |
| 2025-11-04 | -8.26 |
| 2025-11-03 | -8.06 |
| 2025-10-31 | -8.86 |
| 2025-10-30 | -8.06 |
| 2025-10-29 | -8.06 |
| 2025-10-27 | -8.06 |
| 2025-10-23 | -8.06 |
| 2025-10-22 | -8.46 |
| 2025-10-21 | -8.06 |
| 2025-10-20 | -8.06 |
| 2025-10-17 | -8.26 |
| 2025-10-16 | -8.46 |
| 2025-10-15 | -8.26 |
| 2025-10-14 | -8.46 |
| 2025-10-09 | -8.46 |
| 2025-10-07 | -8.66 |
| 2025-10-06 | -8.86 |
| 2025-10-03 | -8.46 |
| 2025-10-02 | -8.46 |
| 2025-10-01 | -8.46 |
| 2025-09-30 | -8.06 |
| 2025-09-29 | -8.46 |
| 2025-09-26 | -8.26 |
| 2025-09-25 | -8.46 |
| 2025-09-24 | -8.66 |
| 2025-09-23 | -8.46 |
| 2025-09-22 | -8.06 |